Skip to main content
. Author manuscript; available in PMC: 2020 Mar 6.
Published in final edited form as: Leukemia. 2019 Sep 6;34(2):380–390. doi: 10.1038/s41375-019-0566-x

Figure 5. Enhancement of the cytotoxic effects of cytarabine in synergism with TAT-SNAG peptide in human AML cells.

Figure 5.

(A-C) The growth of human AML cells after different treatments. The cells were cultured in RPMI1640 containing 10% fetal bovine serum treated with saline alone, cytarabine alone, the combination of cytarabine and control peptide (CP), or the combination of cytarabine and TAT-SNAG peptide (SP). The cell number was counted at different time points (n = 3). (A) THP-1, (B) NOMO-1, (C) NOMOMAC-6.

Data are representative of three independent experiments. All data are represented as mean ± SD. Two-tailed Student’s t-tests were used to assess statistical significance (** P < 0.01). See also Supplemental Figure 17.